Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Blood

Volumn 126, Issue 16, 2015, Pages 1893-1901

  Offner, Fritz ^a   Samoilova, Olga ^b   Osmanov, Evgenii ^c   Eom, Hyeon Seok ^d   Topp, Max S ^e   Raposo, João ^f   Pavlov, Viacheslav ^g   Ricci, Deborah ^h   Chaturvedi, Shalini ⁱ   Zhu, Eugene ^h   Van De Velde, Helgi ⁱ   Enny, Christopher ^h   Rizo, Aleksandra ^h   Ferhanoglu, Burhan ^j  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LOBACHEVSKY STATE UNIVERSITY OF NIZHNY NOVGOROD   (Russian Federation)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d National Cancer Center   (South Korea)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f HOSPITAL DE SANTA MARIA   (Portugal)

^g MEDICAL RADIOLOGICAL RESEARCH CENTER   (Russian Federation)

^h LLC   (United States)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^j KOÇ UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; ANEMIA; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART ARREST; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEURALGIA; NEUTROPENIA; NON GERMINAL CENTER B CELL LIKE DIFFUSE LARGE B CELL LYMPHOMA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SENSORY NEUROPATHY; SEPTIC SHOCK; THROMBOCYTOPENIA; TIME TO NEXT LYMPHOMA THERAPY; TIME TO TREATMENT; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RITUXIMAB; SURVIVAL RATE; VINCRISTINE;

EID: 84944187184     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-632430     Document Type: Conference Paper

References (85)

1. Cultrera JL, Dalia SM. Diffuse large B-cell lymphoma: Current strategies and future directions. Cancer Contr. 2012; 19(3): 204-213.
2. Fayad L, Younes A. Novel treatment strategies for aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother. 2006; 7(6): 733-748.
3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769): 503-511.
4. Lenz G, Wright G, Dave SS, et al; Lymphoma/ Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22): 2313-2323.
5. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 2005; 23(26): 6351-6357.
6. Nedomova R, Papajik T, Prochazka V, Indrak K, Jarosova M. Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 157(3): 239-247.
7. Rosenwald A,Wright G, ChanWC, et al; Lymphoma/ Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25): 1937-1947.
8. Bea S, Zettl A, Wright G, et al; Lymphoma/ Leukemia Molecular Profiling Project. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005; 106(9): 3183-3190.
9. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002; 8(1): 68-74.
10. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003; 100(17): 9991-9996.
11. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009; 15(17): 5494-5502.
12. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1): 275-282.
13. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011; 29(2): 200-207.
14. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009; 113(24): 6069-6076.
15. Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study. J Clin Oncol. 2011; 29(31): 4079-4087.
16. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013; 12(3): 229-243.
17. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003; 198(6): 851-862.
18. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Clinical Oncology (NCCN Guidelines): Non-Hodgkin's Lymphomas. Version 4.2014. Fort Washington, PA: NCCN; 2014.
19. Ghielmini M, Vitolo U, Kimby E, et al; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013; 24(3): 561-576.
20. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008; 26(28): 4587-4594.
21. Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2008; 111(12): 5509-5514.
22. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008; 26(3): 447-454.
23. Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffinembedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008; 112(8): 3425-3433.
24. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12): 1861-1874.
25. Hailfinger S, Lenz G, Ngo V, et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma [published correction appears in Proc Natl Acad Sci USA. 2013; 110(7): 2677].
26. Proc Natl Acad Sci USA. 2009; 106(47): 19946-19951.
27. Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factorkappaB pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008; 111(7): 3701-3713.
28. Ngo VN, Davis RE, Lamy L, et al. A loss-offunction RNA interference screen for molecular targets in cancer. Nature. 2006; 441(7089): 106-110.
29. Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-kappaB subunits in head and neck cancer. Clin Cancer Res. 2008; 14(13): 4175-4185.
30. Ayala G, Yan J, Li R, et al. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008; 14(22): 7511-7518.
31. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001; 61(9): 3535-3540.
32. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002; 277(19): 16639-16647.
33. Bu R, Hussain AR, Al-Obaisi KA, Ahmed M, Uddin S, Al-Kuraya KS. Bortezomib inhibits proteasomal degradation of IkBa and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. Leuk Lymphoma. 2014; 55(2): 415-424.
34. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011; 29(6): 690-697.
35. Elstrom RL, Andemariam B, Martin P, et al. Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2012; 53(8): 1469-1473.
36. Mounier N, Ribrag V, Haioun C, et al. All B lymphoma subtypes do not share similar outcome after frontline R-CHOP plus bortezomib treatment: A randomized phase 2 trial from the Groupe d'etude des lymphomes de l'adulte (GELA). Ann Oncol. 2008; 19(Suppl 4). Abstract 135.
37. Robak T, Huang H, Jin J, et al; LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015; 372(10): 944-953.
38. Millennium Pharmaceuticals, Inc. VELCADE (bortezomib) for injection. For subcutaneous or intravenous use (October 2014, Revision 17). Cambridge, MA: Millennium Pharmaceuticals; 2014.
39. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5): 579-586.
40. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329(14): 987-994.
41. Chen J, Guo L, Peiffer DA, et al. Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues. Int J Cancer. 2008; 122(10): 2249-2254.
42. Juweid ME, Stroobants S, Hoekstra OS, et al; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007; 25(5): 571-578.
43. National Cancer Institute Common Terminology Criteria for Adverse Events v4.03. Bethesda, MD: National Cancer Institute; 2010.
44. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985; 69(12): 1375-1381.
45. Maurer MJ, Ghesquières H, Jais JP, et al. Eventfree survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014; 32(10): 1066-1073.
46. Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013; 381(9880): 1817-1826.
47. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab- CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial. Lancet Oncol. 2013; 14(6): 525-533.
48. Pfreundschuh M, Schubert J, Ziepert M, et al; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD201 B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol. 2008; 9(2): 105-116.
49. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013; 87(2): 146-171.
50. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. Br J Cancer. 2011; 105(11): 1684-1692.
51. Coutinho R, Clear AJ, Owen A, et al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: Implications for therapeutic strategies. Clin Cancer Res. 2013; 19(24): 6686-6695.
52. Seymour JF, Pfreundschuh M, Trnený M, et al; MAIN Study Investigators. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: Final MAIN study outcomes. Haematologica. 2014; 99(8): 1343-1349.
53. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al; Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB). Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011; 117(18): 4836-4843.
54. Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: A meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014; 14(6): 460-467.e2.
55. Copie-Bergman C, Gaulard P, Leroy K, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: A GELA study. J Clin Oncol. 2009; 27(33): 5573-5579.
56. Molina TJ, Canioni D, Copie-Bergman C, et al. Young patients with non-germinal center B-celllike diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: Analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol. 2014; 32(35): 3996-4003.
57. Gang AO, Pedersen MO, Knudsen H, et al. Cell of origin predicts outcome to treatment with etoposidecontaining chemotherapy in young patients with highrisk diffuse large B-cell lymphoma. Leuk Lymphoma. 2015; 56(7): 2039-2046.
58. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008; 26(16): 2717-2724.
59. Cuccuini W, Briere J, Mounier N, et al. MYC1 diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012; 119(20): 4619-4624.
60. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008; 319(5870): 1676-1679.
61. Young RM, Shaffer AL III, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015; 52(2): 77-85.
62. Wilson WH, Gerecitano GF, Goy A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): Interim results of a multicenter, open-label, phase 2 study [abstract]. Blood. 2012; 120(21). Abstract 686.
63. Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study. Lancet Oncol. 2014; 15(9): 1019-1026.
64. Chaiwatanatorn K, Stamaratis G, Opeskin K, Firkin F, Nandurkar H. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracyclinebased chemotherapy with and without rituximab. Leuk Lymphoma. 2009; 50(10): 1666-1675.
65. Crump M, Leppa S, Fayad L, et al. A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: The Prelude Trial [abstract]. Blood. 2013; 122(21). Abstract 371.
66. Espinosa I, Briones J, Bordes R, et al. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma. Ann Hematol. 2006; 85(9): 597-603.
67. Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol. 2005; 18(10): 1377-1384.
68. Li S, Phong M, Lahn M, et al. Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas. Biol Direct. 2007; 2: 8.
69. Riihijarvi S, Koivula S, Nyman H, Rydström K, Jerkeman M, Leppä S. Prognostic impact of protein kinase C beta II expression in R-CHOPtreated diffuse large B-cell lymphoma patients. Mod Pathol. 2010; 23(5): 686-693.
70. Schaffel R, Morais JC, Biasoli I, et al. PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma. Mod Pathol. 2007; 20(3): 326-330.
71. Hinz M, Scheidereit C. The IkB kinase complex in NF-kB regulation and beyond. EMBO Rep. 2014; 15(1): 46-61.
72. Ceribelli M, Kelly PN, Shaffer AL, et al. Blockade of oncogenic IkB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci USA. 2014; 111(31): 11365-11370.
73. Steinhardt JJ, Gartenhaus RB. Promising personalized therapeutic options for diffuse large B-cell lymphoma subtypes with oncogene addictions. Clin Cancer Res. 2012; 18(17): 4538-4548.
74. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459(7247): 717-721.
75. Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-kB in lymphoid malignancies. Immunol Rev. 2012; 246(1): 359-378.
76. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011; 117(8): 2319-2331.
77. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010; 34(3): 327-340.
78. Tomita N. BCL2 and MYC dual-hit lymphoma/ leukemia. J Clin Exp Hematop. 2011; 51(1): 7-12.
79. Lin P, Medeiros LJ. High-grade B-cell lymphoma/ leukemia associated with t(14; 18) and 8q24/MYC rearrangement: A neoplasm of germinal center immunophenotype with poor prognosis. Haematologica. 2007; 92(10): 1297-1301.
80. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/ t(14; 18)(q32; q21): An aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012; 25(1): 145-156.
81. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28): 3460-3467.
82. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013; 121(20): 4021-4031.
83. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28): 3452-3459.
84. Valera A, López-Guillermo A, Cardesa-Salzmann T, et al; Grup per l'Estudi dels Limfomes de Catalunya i Balears (GELCAB). MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013; 98(10): 1554-1562.
85. Furman RR, Martin P, Ruan J, et al. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010; 116(23): 5432-5439.